Primary biliary cholangitis (formerly primary biliary cirrhosis) is a chronic, progressive, autoimmune, cholestatic liver disease more common in middle-aged women. It is characterized by destruction of small to medium bile ducts leading to cholestasis and frequently, end-stage liver disease.
Diagnostic features are chronic biochemical cholestasis, presence of antimitochondrial antibodies and the characteristic liver biopsy findings.
Treatment with capecitabine after surgery for biliary tract cancer improves overall survival (OS) by 15 months compared with observation after surgery, according to the BILCAP* study presented at the ASCO 2017 Annual Meeting in Chicago, Illinois, US.
Antibiotic use among veterans with cirrhosis and upper gastrointestinal (GI) bleeding has improved over the course of 8 years, according to data from a recent study, which also showed that timely administration of antibiotics such as fluoroquinolones or third-generation cephalosporins can cut 30-day mortality by 30 percent in this population.
Mortality, length of stay (LOS) and hospital charges are significantly higher in chronic liver disease (CLD) patients with fractures, a recent study has shown. These findings are also associated with increased infection, bleeding and poorer wound healing.
New drug applications approved by US FDA as of 16 - 30 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.